Market closed
Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Ticker
$MLYS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
51
Website
MLYS Metrics
BasicAdvanced
$618M
-
-$3.66
1.45
-
Price and volume
Market cap
$618M
Beta
1.45
52-week high
$18.38
52-week low
$8.69
Financial strength
Current ratio
14.021
Quick ratio
13.532
Management effectiveness
Return on assets (TTM)
-52.56%
Return on equity (TTM)
-82.24%
Valuation
Price to book
3.23
Price to tangible book (TTM)
3.23
Price to free cash flow (TTM)
-3.617
Growth
Earnings per share change (TTM)
84.38%
3-year earnings per share growth (CAGR)
-2.01%
MLYS News
AllArticlesVideos
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
GlobeNewsWire·1 week ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
24/7 Wall Street·2 weeks ago
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $618M as of April 06, 2025.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of April 06, 2025.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of April 06, 2025.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
